Results from clinical trials conducted by the immune tolerance network (ITN) under the National Institute of Allergies and Infectious Diseases (NIAID), a part of the National Institute of Health (NIH) gave promising results in the form of possible long-term remission of multiple sclerosis in the participating patients. Multiple sclerosis is a condition that causes the body’s immune system to attack and destroy the central nervous system in its victims. The most prevalent symptoms of multiple sclerosis include chronic pains, general weakness, fatigue, and difficulties while communicating. Currently, the most common type of treatment for MS is medication.
However, in most cases, the condition relapses and the symptoms eventually worsen. 69% of the participants completed the treatment without any cases of new brain lesions, recurring multiple sclerosis symptoms, or any progression in their disability. This new MS treatment, dubbed High-dose Immunosuppressive Therapy, and Autologous Hematopoietic Cell Transplant (HDIT/HCT) gives a flicker of hope to patients suffering from this devastating conditions. However, experts maintain that more trials need to be done until higher success rates can be guaranteed. The clinical trials lasted for five years, and during that period, most of the participants’ MS remained in remission, and the condition appeared to have been stabilized.
About Shiva Gopal Vasishta
Dr. Shiva Gopal Vasishta is a New Jersey based neurologist with over forty years of practice. He is associated with the Kennedy University Hospital in Voorhees, NJ. Shiva Gopal Vasishta attended Nagpur Government Medical College and later Boston City Hospital where he attended and completed his residency. Dr. Shiva Gopal Vasishta is a member of the group practice, Eastern Neurodiagnostic Associates, where he currently practices. Shiva Gopal Vasishta is one of the most respected neurologists in the state of New Jersey, identifying and treating disorders of the brain, the nervous system, and spinal cord.